ZVSA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to ZyVersa Therapeutics's net margin of -49.65%. ZyVersa Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3528.45%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that ZyVersa Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe ZyVersa Therapeutics is more attractive than NovaBay Pharmaceuticals.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ZyVersa Therapeutics's net income of -$2.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Omeros has a net margin of -- compared to ZyVersa Therapeutics's net margin of --. ZyVersa Therapeutics's return on equity of -- beat Omeros's return on equity of --.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3528.45%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 466.93%. Given that ZyVersa Therapeutics has higher upside potential than Omeros, analysts believe ZyVersa Therapeutics is more attractive than Omeros.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omeros has a beta of 2.421, suggesting its more volatile than the S&P 500 by 142.108%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than Omeros quarterly revenues of --. ZyVersa Therapeutics's net income of -$2.4M is higher than Omeros's net income of -$32.2M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to ZyVersa Therapeutics's net margin of --. ZyVersa Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3528.45%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than ZyVersa Therapeutics, analysts believe Palatin Technologies is more attractive than ZyVersa Therapeutics.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. ZyVersa Therapeutics's net income of -$2.4M is higher than Palatin Technologies's net income of --. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to ZyVersa Therapeutics's net margin of --. ZyVersa Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3528.45%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 640.74%. Given that ZyVersa Therapeutics has higher upside potential than Theriva Biologics, analysts believe ZyVersa Therapeutics is more attractive than Theriva Biologics.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. ZyVersa Therapeutics's net income of -$2.4M is higher than Theriva Biologics's net income of -$4.4M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.